Effectivity of a T-Cell-Adapted Induction Therapy With Anti-Thymocyte Globulin (Sangstat)

T-cell-adapted ATG induction therapy can be a helpful tool for individualized immunosuppression. It is not associated with an increased rate of rejection. Lower doses of immunosuppression help to minimize the rates of infection. In addition, cytolytic induction therapy combined with reduced ATG results in significant cost reduction.